<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="229231">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096603</url>
  </required_header>
  <id_info>
    <org_study_id>ACD2601g</org_study_id>
    <nct_id>NCT00096603</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g</brief_title>
  <official_title>An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open label, multicenter study designed to evaluate the safety and tolerability of
      efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque
      psoriasis who previously participated in Study ACD2600g.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <enrollment>450</enrollment>
  <condition>Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva (efalizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Previous participation in Study ACD2600g

          -  For women of childbearing potential, continued use of an acceptable method of
             contraception for the duration of the study

        Exclusion Criteria:

          -  Any medical condition that, in the judgment of the investigator, would jeopardize the
             subject's safety following exposure to Efalizumab
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 19, 2014</lastchanged_date>
  <firstreceived_date>November 12, 2004</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
